Stemokin / Neogen: Ile-Glu-Trp and hematopoiesis — US6159940A
Vladislav I. Deigin, Andrei M. Korotkov · 2000 · US6159940A · patent family 26653668
Published 2000-12-12.
Reported patent results
Reported findings
Some animal survival and immune-cell observations were favorable, without an established human treatment result.
Ile-Glu-Trp/Stemokin preclinical hematopoiesis, immune and tumor-model experiments; the description recommends subsequent clinical testing.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Tumor-model survival descriptions | Lifetime reported approximately 4 days longer after peptide-related tumor-cell treatment and 15 days longer in a combination experiment | Different experimental conditions; not patient survival |
| Longer combination observation | An approximately 20-day survival extension and survivors at 60 days described for another combination | Do not assign the combination effect to Ile-Glu-Trp alone |
| Animal observations | No deaths reported during the described 30-day toxicity observation; selected thymus/spleen cell counts increased | These observations do not establish a human safety margin · 30 days |
Different animal protocols and combinations cannot be pooled. No reliable human immune-restoration or cancer-treatment effect is established by this disclosure.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. The claimed peptide class includes Ile-Glu-Trp explicitly in a method directed at hematopoiesis.
The family contains multiple sequences; a peptide use claim is not proof of broad clinical immune restoration.
- Publication
- US6159940A ↗ · 2000-12-12
- Earliest priority / filing
- 1996-02-28 / 1999-06-28
- Original applicant / assignee
- Immunotech Developments Inc
- Indexed status
- Expired - Lifetime · checked 2026-11-06
- Patent family
- 26653668 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method for modulating hemopoiesis
Inventors: Vladislav I. Deigin; Andrei M. Korotkov.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The family contains multiple sequences; a peptide use claim is not proof of broad clinical immune restoration.
- Different animal protocols and combinations cannot be pooled. No reliable human immune-restoration or cancer-treatment effect is established by this disclosure.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-26653668. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Vladislav I. Deigin, Andrei M. Korotkov. Stemokin / Neogen: Ile-Glu-Trp and hematopoiesis — US6159940A US6159940A · patent family 26653668 2000.
Molekul research summary: https://molekul.io/research/patent-us6159940a. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry